Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
Non-Hodgkin's Lymphoma
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "Non-Hodgkin's Lymphoma" in MCE Product Catalog:
52
Research Areas:
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
6
6 Cited Publications
Synonyms: Methylglyoxal-bis(guanylhydrazone); MGBG; Methyl-GAG
Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity. Mitoguazone is a brain-penetrant and competitive S-adenosyl-methionine decarboxylase (SAMDC) inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces cell apoptosis. Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma treatment .
Cat. No.: HY-P99289
CAS No.: 205923-57-5
Synonyms: Antibody hLL 2; AMG-412
Target:
Research Areas:
Cat. No.: HY-P9959
CAS No.: 635715-01-4
Synonyms: CMC-544; PF-5208773; WAY-207294
Target:
Research Areas:
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody Inotuzumab (HY-P99264) conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia .
Synonyms: LP-168
Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 0.11 nM against wild-type BTK and an IC50 of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma .
Target:
Research Areas:
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) .
Cat. No.: HY-P991085
Target:
Research Areas:
Cat. No.: HY-P991647
Cat. No.: HY-106634R
CAS No.: 459-86-9
Synonyms: Methylglyoxal-bis(guanylhydrazone) (Standard); MGBG (Standard); Methyl-GAG (Standard)
Target:
Mitoguazone (Standard) is the analytical standard of Mitoguazone. This product is intended for research and analytical applications. Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity. Mitoguazone is a brain-penetrant and competitive S-adenosyl-methionine decarboxylase (SAMDC) inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces cell apoptosis. Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma treatment .
Cat. No.: HY-153939S
Purity: 99.57%
Synonyms: RG7388-d3-1
Cat. No.: HY-P990954
CAS No.: 2850355-94-9
Synonyms: IMM-0306
Amulirafusp alfa (IMM-0306) is a fusion protein of CD20 monoclonal antibody (mAb) with the CD47 binding domain of SIRPα, with human CD20 Kd 2.45 nM and human CD47 Kd 4.91 nM. Amulirafusp alfa binds to CD20 and CD47 on B cells, engages FcɣR, blocks CD47-SIRPα interaction, activates macrophages, NK cells, and complement cascade, mediates phagocytosis and cytotoxicity, inhibits apoptosis of Jurkat-CSR cells, reverses IL-16 tumor-promoting effects, and binds human/cynomolgus CD47 but not mouse/rat CD47. Amulirafusp alfa can be used for the research of hematological malignancies, relapsed or refractory CD20-positive B-cell non-Hodgkin’s lymphoma, relapsed or refractory B-cell non-Hodgkin lymphoma, and activated B-cell-like diffuse large B-cell lymphoma .
Cat. No.: HY-101798
CAS No.: 2058116-52-0
MDVN1003 is a Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ) dual inhibitor which prevents the activation of B cells and inhibits the phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase 1/2 (ERK 1/2). MDVN1003 can be used for non-Hodgkin’s lymphoma (NHL) research .
Cat. No.: HY-15676R
CAS No.: 1229705-06-9
Synonyms: RG7388 (Standard)
Idasanutlin (Standard) (RG7388 (Standard)) is the analytical standard of Idasanutlin (HY-15676). This product is intended for research and analytical applications. Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
Cat. No.: HY-P992417
Cat. No.: HY-P9959A
CAS No.: 635715-01-4
Synonyms: CMC-544 (solution); PF-5208773 (solution); WAY-207294 (solution)
Target:
Research Areas:
Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
